Immix Biopharma (IMMX) vs Obsidian Therapeutics (OBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Obsidian Therapeutics is the larger company by market cap ($815.4 million vs $786.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMX | OBX |
|---|---|---|
| Share price | $9.49 | $13.20 |
| Market cap | $786.75M | $815.40M |
| 1-day change | -1.56% | -0.15% |
| YTD return | +81.45% | — |
| 1-year return | +278.09% | — |
| EPS (TTM) | $-0.88 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.10 | $49.97 |
| 52-week low | $2.31 | $12.16 |
| Distance from 52-week high | -37.15% | -73.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +156.06% | +195.45% |
| Average volume | 1.66M | 364.58K |
| Shares outstanding | 82.90M | 61.77M |
| Employees | 21 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
IMMX vs OBX FAQ
Which is bigger, Immix Biopharma or Obsidian Therapeutics?
Obsidian Therapeutics (OBX) is larger, with a market capitalization of $815.40M compared with $786.75M for Immix Biopharma (IMMX).
Are Immix Biopharma and Obsidian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.